Table 1.
Baseline characteristics of study cohort stratified by presence or absence of an outcome CVD event
| Characteristic, N (% by column) unless specified |
Total (N=32 192) | CVD event (N=4010) | No CVD event (N=28 182) |
| Female | 19 304 (59.9) | 1859 (46.4) | 12 898 (45.8) |
| Age (median, (IQR)) | 74 (62–80) | 79 (69–80) | 73 (62–80) |
| Non-Hispanic white | 20 230 (62.8) | 2449 (61.1) | 17 781 (63.1) |
| Asian | 3864 (12.0) | 457 (11.4) | 3407 (12.1) |
| Hispanic | 2938 (6.0) | 276 (6.9) | 1662 (5.9) |
| African-American | 497 (1.5) | 88 (2.2) | 409 (1.5) |
| Missing race/ethnicity | 5085 (15.8) | 658 (16.4) | 4427 (15.7) |
| Total cholesterol (mean (SD)) | 175.8 (41.0) | 173.1 (42.2) | 176.1 (40.8) |
| HDL cholesterol, (mean (SD)) | 52.9 (16.0) | 52.2 (16.2) | 53.0 (15.9) |
| Systolic blood pressure, (mean (SD)) | 130.6 (19.1) | 133.2 (20.5) | 130.2 (18.9) |
| On anti-hypertensives | 20 653 (64.2) | 2713 (67.7) | 17 940 (63.7) |
| Antiplatelet medication use (clopidogrel, ticagrelor, prasugrel) | 4514 (14.0) | 598 (14.9) | 3916 (13.9) |
| History of type 2 diabetes | 7501 (23.3) | 1231 (30.7) | 6270 (22.2) |
| Current smoking | 1628 (5.1) | 234 (5.8) | 1394 (4.9) |
| On statin therapy | 15 724 (48.8) | 2052 (51.2) | 13 672 (48.5) |
| Coronary artery disease | 16 221 (50.4) | 2010 (50.1) | 14 211 (50.4) |
| Cerebrovascular disease | 8647 (26.9) | 1068 (26.6) | 7579 (26.9) |
| Peripheral arterial disease | 2416 (7.5) | 450 (11.2) | 1966 (7.0) |
| Polyvascular disease | 3449 (10.7) | 559 (13.9) | 2890 (10.3) |
| Atrial fibrillation | 4972 (15.4) | 679 (16.9) | 4293 (15.2) |
| Heart failure | 2452 (7.6) | 387 (9.7) | 2065 (7.3) |
| eGFR <60 | 8340 (25.9) | 1207 (30.1) | 7133 (25.3) |
| History of CABG | 5019 (15.6) | 773 (19.3) | 4246 (15.1) |
| TIMI 2°P score (mean, (SD)) | 2.91 (1.43), N=13 821 |
2.98 (1.32), N=2051 |
2.90 (1.45), N=11 770 |
CABG, coronary artery bypass grafting; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate.